Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : NT-0796
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of NT-0796 Efficacy & Safety in Obese Adults With/Without Type 2 Diabetes
Details : NT-0796 is a Other Small Molecule drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Obesity-associated with Diabetes Mellitus, Type 2.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 09, 2025
Lead Product(s) : NT-0796
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : NT-0796
Therapeutic Area : Immunology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
NodThera's NT-0796 Meets Primary Endpoint in Inflammation Reversal in Obese Subjects
Details : NT-0796 is an oral, brain-penetrant NLRP3 inflammasome inhibitor, being investigated on inflammation in obese participants at risk of cardiovascular disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 12, 2024
Lead Product(s) : NT-0796
Therapeutic Area : Immunology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : NT-0796
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Effects of NT-0796 in Obese Participants at Risk of Cardiovascular Disease
Details : NT-0796 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Cardiovascular Diseases.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 13, 2023
Lead Product(s) : NT-0796
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : NT-0796 is a novel chemotype, designed as an orally bioavailable, brain penetrant NLRP3 inhibitor. NT-0796 has completed its Phase 1 study confirming brain penetration with excellent pharmacokinetic (PK) & pharmacodynamic (PD) profiles.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 21, 2022
Lead Product(s) : NT-0167
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Organovo Holdings
Deal Size : $55.0 million
Deal Type : Series B Financing
NodThera Announces Close of $55 Million Series B Financing
Details : Proceeds to support advancement of pipeline of small molecule NLRP3 inflammasome inhibitors, including continued progression of NT-0167 through clinical development.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
June 03, 2020
Lead Product(s) : NT-0167
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Organovo Holdings
Deal Size : $55.0 million
Deal Type : Series B Financing